Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours Β· Estimated delivery Sep 29 - Oct 4
Phase 2 clinical trials of retatrutide, including the landmark studies published in the New England Journal of Medicine in 2023, primarily evaluated the drug's efficacy and safety in terms of weight reduction, cardiovascular markers, and gastrointestinal tolerability
By modulating these interconnected pathways, retatrutide serves as a model compound for investigating multi-receptor incretin signaling, energy balance, and metabolic regulation
PubMed laboratory research record [PMID: 39732202] PubMed record related to this compound for laboratory literature review
Bulk-forming agents
US$ 23.15
US$ 21.80
US$ 23.21
